Actively Recruiting
Phase III Study of Intrathecal Rugonersen Versus Sham in Children and Adults With Angelman Syndrome Including a 2-Year Extension
Led by OHB Pediatrics Ltd. · Updated on 2026-10-20
165
Participants Needed
6
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of intrathecally administered rugonersen in children and adults with Angelman syndrome, a genetic condition. This Phase III, randomized, double-blind, sham-controlled study involves up to 165 participants and aims to compare rugonersen with a sham procedure. After the initial treatment phase, an open-label extension lasting about 116 weeks 2 years will further assess long-term effects of rugonersen in this population. Participants will receive either the study drug rugonersen or a sham procedure administered intrathecally. The study includes a double-blind phase where neither participants nor investigators know the assigned intervention. The extension phase offers all participants the chance to receive rugonersen openly to evaluate ongoing efficacy and safety. Treatments are administered via lumbar puncture under sedation or anesthesia as appropriate. During the trial, participants will have regular assessments including cognitive and communication evaluations using Bayley-4 scales at baseline and Week 56. Other measures include clinician global impressions, EEG monitoring, and safety checks for serious adverse events. Caregivers are involved in reporting and assessments. The study lasts several years with long-term follow-up to monitor treatment effects and safety outcomes.
CONDITIONS
Brief Title
BEACON - Phase III Clinical Study of Rugonersen in Angelman Syndrome.
Research Team
B
Brenda Vincenzi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here